Thus, simultaneous multiple interaction T-cell engaging (SMITE) consisting of two separated canonical BiTE antibodies has been developed, both of the antibodies target TAAs on the one side while binding to either CD3 or CD28 on the other, providing additional costimulatory activation to enhance anti-tumor activity than either BiTE antibody alone [139]. Here, CD28 is linked to neoplasm.